News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
U.S. FDA Staff Eyes Safety of Novartis AG’s MS Drug, Gilenia
June 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. regulators expressed concern about potential side effects of Novartis AG's multiple sclerosis pill in patients most at risk for complications.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Food and Drug Administration (FDA)
Novartis
MORE ON THIS TOPIC
Layoffs
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
July 17, 2025
·
1 min read
·
Heather McKenzie
IN PARTNERSHIP WITH IQVIA
AI Is Taking Over Drug Safety Monitoring–But There’s One Thing It Can’t Replace
July 17, 2025
·
1 min read
·
Lori Ellis
Podcast
FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease
July 16, 2025
·
1 min read
·
Heather McKenzie
Layoffs
HHS Begins Formally Laying Off Employees
July 15, 2025
·
2 min read
·
Tristan Manalac
